Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: Amgen appeals biosimilar case to CAFC

    Amgen Inc. (NASDAQ:AMGN) filed an appeal to the U.S. Court of Appeals for the Federal Circuit (CAFC) Wednesday, after a district court last week denied the company's motions intended to prevent the Sandoz unit of …

    Published on 3/25/2015
  • COMPANY NEWS: Emergent's anthrax treatment gets FDA nod

    FDA approved a BLA for Anthrasil anthrax immune globulin IV (AIGIV) from Emergent BioSolutions Inc. (NYSE:EBS) to treat inhaled anthrax. The drug, developed using plasma collected from healthy donors vaccinated with the…

    Published on 3/25/2015
  • COMPANY NEWS: FDA approves Eylea for diabetic retinopathy

    FDA approved Eylea aflibercept from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat diabetic retinopathy in patients with diabetic macular edema (DME). The human fusion protein that binds all forms of VEGF-A and …

    Published on 3/25/2015
  • COMPANY NEWS: Management tracks

    Pain company Egalet Corp. (NASDAQ:EGLT) hired Wendy Niebler as SVP of clinical development and medical affairs, a newly created position. Niebler was VP and head of global medical affairs at PTC Therapeutics Inc. (…

    Published on 3/25/2015
  • COMPANY NEWS: BMS scoops up Novo autoimmune program

    Bristol-Myers Squibb Co. (NYSE:BMY) acquired an exclusive global license to a research program from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) that modulates the innate immune system to treat autoimmune diseases. Specifics of…

    Published on 3/24/2015
  • COMPANY NEWS: Calico, QB3 start research collaboration

    Calico LLC (South San Francisco, Calif.) and the California Institute for Quantitative Biosciences (QB3) started a four-year partnership to investigate the biology of aging and age-related diseases.Calico will fund …

    Published on 3/24/2015
  • COMPANY NEWS: Management tracks

    The Innovative Medicines Initiative (IMI) named Marc de Garidel as chair of its governing board. Garidel succeeds Roch Doliveux, who retired last year. Garidel is chairman and CEO of Ipsen Group (Euronext:IPN; Pink:…

    Published on 3/24/2015
  • COMPANY NEWS: Biogen drops Idec from name

    Biogen (NASDAQ:BIIB) changed its name from Biogen Idec Inc. The company had been called Biogen Idec since Biogen Inc. merged with Idec Pharmaceuticals Corp. in 2003.Biogen's shares fell $12.25 to $463.73 on Monday.

    Published on 3/23/2015
  • COMPANY NEWS: EC approves Novo's Saxenda

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said the European Commission approved an MAA for Saxenda liraglutide for weight management as an adjunct to diet and exercise in obese adults or in overweight adults with at least …

    Published on 3/23/2015
  • COMPANY NEWS: Forma, Cancer Research Technology launch two spinouts

    Forma Therapeutics Inc. (Watertown, Mass.) and Cancer Research Technology Ltd. (London, U.K.), the commercial arm of the not-for-profit Cancer Research U.K., launched two virtual companies to develop compounds against …

    Published on 3/23/2015
  • COMPANY NEWS: ImmunoGen surges on ADC deal with Takeda

    ImmunoGen Inc. (NASDAQ:IMGN) gained $1.25 (17%) to $8.69 on Monday on news that Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) licensed exclusive rights to the biotech's antibody-drug conjugate (ADC) technology to develop …

    Published on 3/23/2015
  • COMPANY NEWS: Management tracks

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) appointed Timothy Wright as EVP of business development, strategy and innovation, effective April 13. Wright was director of the Drug Discovery and Development Institute …

    Published on 3/23/2015
  • COMPANY NEWS: Pfizer, Lilly to resume Phase III tanezumab program

    Pfizer Inc. (NYSE:PFE) and Eli Lilly and Co. (NYSE:LLY) said they would resume Phase III development of tanezumab to treat chronic pain after FDA lifted a partial clinical hold on the compound. In December 2012, FDA …

    Published on 3/23/2015
  • COMPANY NEWS: Zai gains China rights to BMS's brivanib

    Bristol-Myers Squibb Co.(NYSE:BMY) granted Zai Laboratory Inc. (Shanghai, China) exclusive rights in China, including Hong Kong and Macau, to oral brivanib to treat oncology indications including hepatocellular …

    Published on 3/23/2015
  • COMPANY NEWS: AstraZeneca, Daiichi in Movantik commercialization deal

    AstraZeneca plc (LSE:AZN; NYSE:AZN) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) partnered to co-commercialize AZ's Movantik naloxegol in the U.S. The peripheral mu opioid receptor (OPRM1; MOR) antagonist is approved to …

    Published on 3/20/2015
  • COMPANY NEWS: Lilly to commercialize biologics discovered in China

    Innovent Biologics Inc. (Suzhou, China) has signed a co-development deal with Eli Lilly and Co. (NYSE:LLY) for biologics discovered in China. Innovent will receive $56 million up front and is eligible for more than $400…

    Published on 3/20/2015
  • COMPANY NEWS: Sanofi, Evotec enter multi-part collaboration

    Evotec AG (Xetra:EVT) gained EUR 0.27 to EUR 3.99 on Friday after it entered a multifaceted collaboration with Sanofi (Euronext:SAN; NYSE:SNY), including a five-year oncology research deal.The companies intend to …

    Published on 3/20/2015
  • COMPANY NEWS: Amicus speeds Amigal submission timeline

    Amicus Therapeutics Inc. (NASDAQ:FOLD) rose $3.11 (33%) to $12.46 on Thursday after the company said it will submit regulatory applications in the U.S. and Europe this year for Amigal migalastat to treat Fabry's disease…

    Published on 3/19/2015
  • COMPANY NEWS: Court sides with Sandoz in Amgen biosimilar case

    The U.S. District Court for the Northern District of California denied motions made by Amgen Inc. (NASDAQ:AMGN) against the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) that would have delayed sales of Zarxio …

    Published on 3/19/2015
  • COMPANY NEWS: FDA panel backs Breo Ellipta for adults, not children

    FDA's Pulmonary-Allergy Drugs Advisory and Drug Safety and Risk Management Advisory committees voted 16-4 to recommend approval of Breo Ellipta fluticasone furoate/vilanterol from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)…

    Published on 3/19/2015
  • COMPANY NEWS: J&J buys single-asset anticoagulant company XO1

    The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) acquired XO1 Ltd. (Cambridge, U.K.), a single-asset cardiovascular company developing preclinical anticoagulant ichorcumab. J&J spokesperson Ellen …

    Published on 3/19/2015
  • COMPANY NEWS: Lilly licenses Hanmi's Btk inhibitor

    Eli Lilly and Co. (NYSE:LLY) obtained exclusive, worldwide rights outside of certain Asian territories to HM71224, an oral Bruton's tyrosine kinase (Btk) inhibitor from Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940). The…

    Published on 3/19/2015
  • COMPANY NEWS: Management tracks

    Cell therapy company Fibrocell Science Inc. (NASDAQ:FCSC) hired Keith Goldan as SVP and CFO. Goldan was SVP and CFO of NuPathe Inc., which was acquired by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).Ophthalmic play …

    Published on 3/19/2015
  • COMPANY NEWS: Management tracks

    Agilent Technologies Inc. (NYSE:A) promoted Mike McMullen from COO to CEO; he will retain his role as president. He succeeds William Sullivan, who will be a company advisor until his retirement on Oct. 31. Trovagene Inc…

    Published on 3/18/2015
  • COMPANY NEWS: FDA reviewers focus on safety of Breo Ellipta

    FDA will ask its Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisory committees to vote on whether to recommend a large pre- or post-approval safety trial to evaluate serious asthma outcomes for Breo …

    Published on 3/17/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993